Universe Pharmaceuticals (NASDAQ: UPC) adjourns 2025 shareholder meeting for lack of quorum

Rhea-AI Filing Summary

Universe Pharmaceuticals INC reported that its 2025 annual general meeting of shareholders, originally convened on August 26, 2025, could not proceed because there were not enough shares represented to meet the required quorum. As a result, the meeting was formally adjourned to September 2, 2025 at 10:00 a.m. Beijing time.

The rescheduled meeting will take place at the company’s principal office at 265 Jingjiu Avenue in the Jinggangshan Economic and Technological Development Zone in Ji’an City, Jiangxi, China. The notice confirms that the company’s chief executive officer, Gang Lai, authorized this report.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission file number: 001-40231

Universe Pharmaceuticals INC

265 Jingjiu Avenue

Jinggangshan Economic and Technological Development Zone

Ji’an, Jiangxi, China 343100

+86-0796-8403309

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Adjournment of Annual General Meeting

On August 26, 2025, Universe Pharmaceuticals INC (the “Company”) convened the 2025 annual general meeting of shareholders (the “2025 Annual General Meeting”). However, due to a lack of quorum, the 2025 Annual General Meeting was adjourned to September 2, 2025, at 10:00 a.m., Beijing Time at 265 Jingjiu Avenue, Jinggangshan Economy and Technology Development Zone, Ji’an City, Jiangxi 343100, the People’s Republic of China.

1

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Universe Pharmaceuticals INC.
Date: August 26, 2025	By:	/s/ Gang Lai
		Gang Lai
		Chief Executive Officer

2

FAQ

What did Universe Pharmaceuticals INC (UPC) disclose in this 6-K?

Universe Pharmaceuticals INC disclosed that its 2025 annual general meeting of shareholders was adjourned due to a lack of quorum and rescheduled to a later date.

Why was Universe Pharmaceuticals INC’s 2025 annual general meeting adjourned?

The 2025 annual general meeting was adjourned because there was a lack of quorum, meaning not enough shares were represented to validly conduct the meeting.

When is Universe Pharmaceuticals INC’s adjourned 2025 annual general meeting scheduled?

The adjourned 2025 annual general meeting is scheduled for September 2, 2025 at 10:00 a.m., Beijing Time.

Where will Universe Pharmaceuticals INC hold the rescheduled 2025 annual meeting?

The rescheduled 2025 annual meeting will be held at 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji’an City, Jiangxi 343100, People’s Republic of China.

Who signed the report related to Universe Pharmaceuticals INC’s adjourned meeting?

The report was signed by Gang Lai, the Chief Executive Officer of Universe Pharmaceuticals INC.

Does this adjournment indicate any change in Universe Pharmaceuticals INC’s business operations?

The disclosure only states that the annual meeting was adjourned and rescheduled due to a lack of quorum; it does not describe changes to business operations.